Phase 2 N=33 Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology
Depression · Anxiety
Primary: Depression Anxiety and Stress Scale (DASS) — 6.14; 5.23; 7.21; 5.62 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Hepatitis C · HIV
Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants
Phase 2 N=379 Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.3; 100.0; 90.9; 100.0 percentage of participants
Phase 2 N=39 Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment — 0.45; -0.03; -0.19 Percentage of HbA1c — p=0.3295
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 2 N=11 Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
HIV Infections
Primary: Patients With Low-density Lipoprotein (LDL) Cholesterol Reduction — 90.9 percentage of participants
Phase 2 N=49 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
Kidney Cancer · Leukemia · Lymphoma
Primary: Incidence of Vincristine-induced Peripheral Neuropathy — 24; 25 participants
Phase 2 N=59 Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Refractory Leukemia · Acute Myelogenous Leukemia
Primary: Best Response as Per Investigator Assessment by Stratum (FAS) — 3.1; 7.4; 0; 3.7 Percentage of Participants
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
Phase 2 N=77 A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants
Phase 2 N=85 S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 29.8 months
Phase 2 N=61 LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Acute Respiratory Distress Syndrome (ARDS)
Primary: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio — 320; 334; 376; 336 SpO2/FiO2 Ratio — p=0.02
Phase 2 N=404 Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care
Stress Disorders, Post-Traumatic
Primary: PTSD Symptoms — 71.1; 71.0 CAPS scores — p=0.97
Phase 2 N=39 Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
Pterygium
Primary: Number of Participants Who Had Recurrence of Pterygia up to 1 Year — 0; 3 participants
Phase 2 N=7 AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants That Experienced a Dose Limiting Toxicity — 0 percentage of participants